和黄医药(00013)：索乐匹尼布 (sovleplenib) 用于治疗温抗体型自身免疫性溶血性贫血患者的中国新药上市申请获受理并获纳入优先审评及突破性治疗品种

智通财经04-29

智通财经APP讯，和黄医药(00013)发布公告，索乐匹尼布(sovleplenib)用于治疗既往至少对糖皮质激素治疗反应不佳的成人温抗体型自身免疫性溶血性贫血(wAIHA)的患者的新药上市申请已获中国国家药品监督管理局(“国家药监局”)受理，并获纳入优先审评。索乐匹尼布是一种开发用于治疗自身免疫性疾病和血液恶性肿瘤的新型、高选择性的口服脾酪氨酸激酶(“Syk”)抑制剂。自身免疫性溶血性贫血(...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2631591630?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-29 18:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2631591630","market":"fut","top_or_hot":-1,"title":"和黄医药(00013)：索乐匹尼布 (sovleplenib) 用于治疗温抗体型自身免疫性溶血性贫血患者的中国新药上市申请获受理并获纳入优先审评及突破性治疗品种","media":"智通财经","content":"<div>\n<p>智通财经APP讯，和黄医药(00013)发布公告，索乐匹尼布(sovleplenib)用于治疗既往至少对糖皮质激素治疗反应不佳的成人温抗体型自身免疫性溶血性贫血(wAIHA)的患者的新药上市申请已获中国国家药品监督管理局(“国家药监局”)受理，并获纳入优先审评。索乐匹尼布是一种开发用于治疗自身免疫性疾病和血液恶性肿瘤的新型、高选择性的口服脾酪氨酸激酶(“Syk”)抑制剂。自身免疫性溶血性贫血(...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1436315.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>和黄医药(00013)：索乐匹尼布 (sovleplenib) 用于治疗温抗体型自身免疫性溶血性贫血患者的中国新药上市申请获受理并获纳入优先审评及突破性治疗品种</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n和黄医药(00013)：索乐匹尼布 (sovleplenib) 用于治疗温抗体型自身免疫性溶血性贫血患者的中国新药上市申请获受理并获纳入优先审评及突破性治疗品种\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-29 18:10 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1436315.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，和黄医药(00013)发布公告，索乐匹尼布(sovleplenib)用于治疗既往至少对糖皮质激素治疗反应不佳的成人温抗体型自身免疫性溶血性贫血(wAIHA)的患者的新药上市申请已获中国国家药品监督管理局(“国家药监局”)受理，并获纳入优先审评。索乐匹尼布是一种开发用于治疗自身免疫性疾病和血液恶性肿瘤的新型、高选择性的口服脾酪氨酸激酶(“Syk”)抑制剂。自身免疫性溶血性贫血(...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1436315.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1436315.html","article_id":"2631591630","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2631591630","pubTimestamp":1777457421,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，和黄医药 发布公告，索乐匹尼布用于治疗既往至少对糖皮质激素治疗反应不佳的成人温抗体型自身免疫性溶血性贫血的患者的新药上市申请已获中国国家药品监督管理局受理，并获纳入优先审评。索乐匹尼布于2026年3月获国家药监局纳入突破性治疗品种，用于治疗温抗体型自身免疫性溶血性贫血。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","BK4531":"中概回港概念","BK4588":"碎股","BK1191":"制药","BK4585":"ETF&股票定投概念","BK1588":"回港中概股","BK1587":"次新股","IPOS":"Renaissance International IPO ETF","00013":"和黄医药","HCM":"和黄医药"},"translate_title":"Chutchison Pharmaceuticals (00013): The Chinese new drug marketing application of sovleplenib for the treatment of patients with warm antibody autoimmune hemolytic anemia was accepted and included in priority review and breakthrough treatment","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPOS":1.5,"HCM":1.5,"00013":1.5},"content_text":"智通财经APP讯，和黄医药(00013)发布公告，索乐匹尼布(sovleplenib)用于治疗既往至少对糖皮质激素治疗反应不佳的成人温抗体型自身免疫性溶血性贫血(wAIHA)的患者的新药上市申请已获中国国家药品监督管理局(“国家药监局”)受理，并获纳入优先审评。索乐匹尼布是一种开发用于治疗自身免疫性疾病和血液恶性肿瘤的新型、高选择性的口服脾酪氨酸激酶(“Syk”)抑制剂。自身免疫性溶血性贫血(AIHA)是一种自身免疫性疾病，是由于产生抗自身红细胞的抗体，而导致红细胞的破坏所造成的疾病。自身免疫性溶血性贫血的发病率估计为每年每十万成人中有0.8-3.0例，患病率估计为每十万成人中有17例，死亡率为8-11%。自身免疫性溶血性贫血中温抗体型是最常见的类型，占所有成人自身免疫性溶血性贫血病例的75-80%。ESLIM-02研究的数据支持了此项新药上市申请。ESLIM-02研究是一项在既往接受过至少一种标准治疗后复发或难治性的原发或继发性温抗体型自身免疫性溶血性贫血成人患者中开展的随机、双盲、安慰剂对照的中国II/III期临床试验。2026年1月，该研究的III期阶段达到了第5至24周治疗期间持久血红蛋白(Hb)应答这一主要终点。研究的III期数据将于即将召开的2026年欧洲血液学协会(EHA)年会上发表。该研究II期阶段的结果已于2025年1月于《柳叶刀·血液病学 (The Lancet Haematology)》发表 ，与安慰剂相比，索乐匹尼布展示出令人鼓舞的血红蛋白获益，前8周的整体应答率为43.8%对比0% ，24周索乐匹尼布治疗期间(包括从安慰剂交叉的患者)的整体应答率为66.7% ，且安全性良好。和黄医药代理首席执行官兼首席财务官郑泽锋先生表示：“我们很高兴提交了索乐匹尼布用于治疗温抗体型自身免疫性溶血性贫血的新药上市申请，并获国家药监局纳入优先审评资格和突破性治疗品种。这是索乐匹尼布提交的第二个适应症上市申请，进一步彰显了其作为一款创新口服Syk抑制剂的广泛潜力。我们期待为治疗选择有限的温抗体型自身免疫性溶血性贫血患者带来这一亟需的治疗方案，同时通过这一重要的新适应症进一步增强我们的血液学产品组合。”索乐匹尼布于2026年3月获国家药监局纳入突破性治疗品种，用于治疗温抗体型自身免疫性溶血性贫血。国家药监局将索乐匹尼布纳入突破性治疗品种，作为用于防治且尚无有效防治手段的严重疾病，及与现有治疗手段相比具有明显临床优势的创新药物。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2631591630","isCrawlerRequest":true}